Related Experiment Videos
[Toxic hepatitis and liver failure under therapy with flutamide]
1Klinik für Innere Medizin, Klinikum "St. Georg" Leipzig. CLuebbert@aol.com
Der Internist
|March 5, 2004
Summary
Flutamide, used for prostate cancer, can cause severe liver damage. While one patient recovered, another died from liver failure, highlighting flutamide
Area of Science:
- Oncology
- Hepatology
- Pharmacology
Background:
- Flutamide is a widely prescribed antiandrogen for prostate cancer treatment.
- Severe hepatotoxicity, though rare, is a known potentially fatal adverse effect of flutamide therapy.
Observation:
- Two prostate cancer patients receiving flutamide presented with varying degrees of liver injury.
- One patient experienced complete recovery after flutamide withdrawal and steroid treatment.
- The second patient developed progressive liver dysfunction and hepatorenal syndrome despite early flutamide cessation.
Findings:
- The case series illustrates differential patient responses to flutamide-induced hepatotoxicity.
- Fulminant hepatic coma led to the death of one patient, marking the first reported fatality from flutamide in Germany.
Implications:
- This study underscores the critical need for vigilant liver function monitoring in patients undergoing flutamide treatment.
- Understanding flutamide metabolism and mechanisms of hepatotoxicity is crucial for risk mitigation.
- The findings may inform clinical guidelines for managing prostate cancer patients at risk of severe drug-induced liver injury.